Darbepoetin alfa - Open Access .click

Results 171 to 180 of about 5,123 (202)

Some of the next articles are maybe not open access.

BioDrugs, 2005
Darbepoetin alfa (Aranesp), Nespo) is an amino acid substituted analog of human erythropoietin (EPO) that promotes erythrocyte survival, proliferation, and differentiation. Approved in Europe and the US for the treatment of anemia associated with chronic kidney disease (CKD), it is characterized by delayed clearance and a more prolonged elimination ...
Dean M, Robinson, Stephanie E, Easthope
openaire +2 more sources

Darbepoetin alfa. Amgen.

Current opinion in investigational drugs (London, England : 2000), 2002
Amgen has launched darbepoetin alfa, synthetic recombinant novel erythropoiesis stimulating protein (NESP), for the treatment of anemia associated with renal disease. The drug was approved by the European Commission in June 2001, under the tradename Aranesp, for the treatment of anemia in chronic kidney failure including patients on and not yet on ...
F, Locatelli, L D, Vecchio
openaire +1 more source

Darbepoetin alfa

Reactions Weekly, 2018
+4 more sources

Darbepoetin-alfa/epoetin-alfa

Reactions Weekly, 2023
openaire +1 more source

A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia

Clinical Therapeutics, 2003
Lee S Schwartzberg
exaly

Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure

Advances in Therapy, 2007
Mehmet Kanbay, Tuncay Delibasi, Faruk Turgut +2 more
exaly

Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia

American Journal of Health-System Pharmacy, 2005
Jon D Herrington
exaly

Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients

Kidney International, 2002
Peter Barany, Peter G Kerr
exaly